D. Teachey

Identifying novel genomic alterations in relapsed childhood B-ALL: a report from the Children's Oncology Group.

Relapsed B-acute lymphoblastic leukemia (B-ALL) generally occurs due to the emergence of subclones resistant to therapy, leading to poor outcome. Here, we describe novel genomic alterations responsible for therapeutic resistance at a subtype level in a clinical trial (AALL1331) which randomized patients to blinatumomab...

MCL1 inhibition exerts potent antileukemic activity by restoring apoptosis in T-lineage acute lymphoblastic leukemia

,

Late effects after novel therapies for childhood cancer: Anticipating the future landscape of health outcomes for survivors.

Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies.

Findings define previously unrecognized interactions between CD38 and targetable pathways and genes in T-ALL and identify rational combinatorial strategies to enhance CD38-directed therapies and reduce relapse risk.

A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial

Early-phase studies of deep B cell depletion with anti-CD19 chimeric antigen receptor (CAR) T have produced prolonged, drug-free remission in refractory autoimmune disease. However, CAR T cell therapy requires lymphodepleting chemotherapy, autologous cell manufacturing and specialized infrastructure, limiting reach to...

SOX11 stimulates γδ T-cell differentiation and synergizes with LMO2 and MYCN to drive γδ-like T-cell acute lymphoblastic leukemia

Functional validation using genetic and transplantation-based mouse models demonstrated that SOX11 cooperates with MYCN to accelerate T-ALL onset and establish a cooperative SOX11–MYCN oncogenic axis driving γδ-like T-ALL.